| Purpose: Exploring the clinical significance of the hypercoagulation state with epithelial ovarian cancer patients. Analyzing connection clinical significance between the expression of GGCX & VKORC1 and hypercoagulable state,superficial comprehend the high risk factors of cancer-related venous thromboembolism.Methods: The EOC tissues and ovarian tissues were collected on women who underwent surgery between 2011/08/04 and 2014/03/19 at Hunan Cancer hospital.There were 135 cases EOC tissues and 25 cases ovarian tissues in our study cohort.Collected the patients’ the data of hypercoagulable state(eg. hemagglutination index, PLT)and clinical pathological parameters,then analyzed the relationship between the data of hypercoagulable state and clinical pathological parameters. The immunohistochemical method is used in this experiment to respectively detect the expression levels of VKORC1 and GGCX in the organization of 135 cases EOC tissues and 25 cases normal tissue. Then analyze the relationship between the expression levels of VKORC1 and GGCX and the data of hypercoagulable state and clinical pathological parameters with the whole patients.Results:1.The PLT count,the level of plasma FIB and DD in EOC is signi ficantly higher than the normal the ovary, and a significant reduction in th e TT, have statistically significant(P < 0.05), and PT, APTT, TT there wa s no significant difference between them(P > 0.05).2.The level of FIB and DD Epithelial in ovarian cancer group with VKO RC1 high expression were significantly higher than that of low expressio n group(P < 0.05), PT, APTT, TT, PLT statistics there was no significant difference between the two(P > 0.05); The level of TT and the DD in Ep ithelial ovarian cancer group with GGCX high expression was higher tha n the low expression group, the statistical difference, and significant reduction in TT(P < 0.05),the level of PT, APTT, PLT and FIB between the two there was no significant statistical difference(P > 0.05).3.The level of plasma FIB, PLT, DD in III+IV phase ovarian cancer pati ents has increased significantly compared with the I + II one, and the leve l of TT was significant decreased, have statistical difference(P < 0.05), t he statistics between PT and APTT, there was no significant difference(P >0.05); The level of Lymph node metastatic cases plasma was decreased significantly(P < 0.05), There was no correlation between lymph node metastasis and the level of PT, APTT, PLT and FIB, DD(P > 0.05); Age, epithelial ovarian cancer histological type, differentiation degree, greater omentum metastasis, high blood coagulation state,There was no signific ant relationship between two(P > 0.05).4.The VKORC1 high expression cases in epithelial ovarian cancer is 108, high expression rate was 91.1%(108/135); There was no VKORC1 high expression in normal ovarian, high expression rate was 0%(0/25), has th e remarkable difference between them(P < 0.05). The GGCX high expres sion cases in epithelial ovarian cancer is 91, high expression rate was 67.4%(91/135); The high expression cases in normal ovarian high expression in normal ovarian is 4, higher expression rate was 16.0%(4/25), there w as the remarkable difference between them(P < 0.05). VKORC1, GGCX protein expression and epithelial ovarian cancer patients’ age, type of orga nization, lymph node metastasis, FIGO staging, greater omentum metasta sis and tissue differentiation degree, There was no significant relationshi p between two(p > 0.05).5.Analyzed the high and low expression of VKORC1 and GGCX influence on prognosis, the expression level of VKORC1 effect on the prognosis without statistical difference(P > 0.05); GGCX high expression is negatively correlated with disease-free Survival(Progression-free Survival, PFS)(P < 0.05), there was no correlation between high GGCX expression and(Overall Survial, OS)(P> 0.05). Conclusion: 1.EOC patients were high blood coagulation, hypercoagulable statecorrelated with progression of epithelial ovarian cancer;2.The high expression of VKORC1 and GGCX promote the blood high condensation state in epithelial ovarian cancer patients. |